Literature DB >> 11345287

Prevalence and severity of asthma, rhinitis, and atopic eczema in 13- to 14-year-old schoolchildren from the northeast of England.

M H Shamssain1, N Shamsian.   

Abstract

OBJECTIVE: To investigate the prevalence and severity of asthma, rhinitis, and atopic eczema in schoolchildren from the northeast of England.
METHODS: We randomly selected 3,000 children from 80 schools. We used the ISAAC (International Study of Asthma and Allergies in Childhood) written questionnaire.
RESULTS: The lifetime prevalence rates of symptoms were: rhinitis, 32.8%; wheezing, 31.3%; hay fever, 23.7%; and self-reported asthma, 22.3%. Rhinitis was reported by 53% and 61% of boys and girls with asthma, respectively. Girls 13 to 14 years of age had higher prevalence rates of asthma, rhinitis, and eczema symptoms than boys; a reverse sex ratio has been shown in this age group. Atopic eczema was reported by 32% of boys with asthma and 37% of girls with asthma.
CONCLUSIONS: The prevalence rates of reported asthma, and symptoms suggestive of asthma, were higher than those previously reported in UK children. The present study would be a suitable baseline for monitoring future trends in the prevalence and severity of asthma and allergic disorders among these children, and provides a framework for further etiologic research into the genetics, lifestyle, environmental, and medical care factors affecting these conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11345287     DOI: 10.1016/S1081-1206(10)62490-8

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  9 in total

1.  Specificity in the association of anxiety, depression, and atopic disorders in a community sample of adolescents.

Authors:  Marcia J Slattery; Marilyn J Essex
Journal:  J Psychiatr Res       Date:  2010-11-25       Impact factor: 4.791

Review 2.  Allergic rhinitis in children : diagnosis and management strategies.

Authors:  William E Berger
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Risk factors for allergic rhinitis in Costa Rican children with asthma.

Authors:  S Bunyavanich; M E Soto-Quiros; L Avila; D Laskey; J M Senter; J C Celedón
Journal:  Allergy       Date:  2009-10-01       Impact factor: 13.146

Review 4.  Dust events, pulmonary diseases and immune system.

Authors:  Nafiseh Esmaeil; Marjan Gharagozloo; Abbas Rezaei; Gabriele Grunig
Journal:  Am J Clin Exp Immunol       Date:  2014-02-27

5.  Prevalence and severity of asthma, rhinitis, and atopic eczema in 13- to 14-year-old schoolchildren from southern Brazil.

Authors:  Arnaldo C Porto Neto; Rafael D'Agostini Annes; Nathalia Mm Wolff; Andréia P Klein; Francisco C Dos Santos; Juliana L Dullius; Marina Gressler; Letícia S Muller; Cristine F Angonese; Sérgio Menna-Barreto
Journal:  Allergy Asthma Clin Immunol       Date:  2006-03-15       Impact factor: 3.406

6.  Asthma prevalence among 16- to 18-year-old adolescents in Saudi Arabia using the ISAAC questionnaire.

Authors:  Mohammed O Al Ghobain; Mohamad S Al-Hajjaj; Mohamad S Al Moamary
Journal:  BMC Public Health       Date:  2012-03-26       Impact factor: 3.295

7.  Clinically diagnosed childhood asthma and follow-up of symptoms in a Swedish case control study.

Authors:  Eduardo Roel; Ashild Faresjö; Olle Zetterström; Erik Trell; Tomas Faresjö
Journal:  BMC Fam Pract       Date:  2005-04-21       Impact factor: 2.497

Review 8.  The Role of Human Milk Immunomodulators in Protecting Against Viral Bronchiolitis and Development of Chronic Wheezing Illness.

Authors:  Dani-Louise Dixon
Journal:  Children (Basel)       Date:  2015-07-07

Review 9.  Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review.

Authors:  Erik-Jonas van de Griendt; Mariska K Tuut; Hans de Groot; Paul L P Brand
Journal:  BMJ Open       Date:  2017-12-28       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.